Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-RIO riociguat discontinuation after BPA in CTEPH
NL-OMON59874Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of riociguat in chronic thromboembolic pulmonary hypertension (CTEPH) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Difference in mean pulmonary artery pressure. Started Oct 2025; status: recruiting.
02
Drugs
riociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NL-OMON59874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59874.